Orbital rhabdomyosarcoma in children

Purpose. To analyze the results of treatment and active monitoring the children with orbital rhabdomyosarcoma (RMS) with an emphasis on vital prognosis. Material and methods. We examined 32 children with RMS (18 boys, 14 girls) aged 2 months to 12 years, whose case history ranged from 1 week to 16 weeks (median, 5 weeks). The median follow-up was 60 months. The tumor was localized in the upper (n = 13), upper internal (n = 9), lower (n = 4), internal (n = 3), and external (n = 3) quadrants. The patients underwent primary surgical treatment: orbitotomy using transcutaneous (n = 26), transconjunctival (n = 2) and subperiosteal access (n = 4) followed by cytological, histological and immunohistochemical tissue verification in all cases. Results. The highest number of RMS cases was noted in in the 2- to 7-year-old group (66 % of patients). All patients were treated in in-patient settings. Complete macroscopic removal of tumor was performed in 17 cases, partial removal in 9 cases, and biopsy sampling in 6 cases. The embryonic type of RMS accounted for 87 % (n = 28), and the alveolar type, for 13 % (n = 6). In the postoperative period all children received combined therapy (systemic polychemotherapy and distant radiation therapy) in in-patient facilities of special oncological and radiological clinics. The survival rate of the whole group was 100%. In the long-term follow-up period (after 3 to 5 years), reconstructive surgeries were performed to correct ptosis and strabismus, and/or spectacle or prismatic correction of complex or mixed astigmatism. In cases of “dry” eye syndrome, conservative local therapy was offered. After orbital exenteration, ectoprosthesis procedures was applied. Conclusion. The analysis of our observations of 32 children with orbital rhabdomyosarcoma showed a 100 % survival rate, which testifies to the importance of timely diagnosis and combined treatment of the tumor.

1. Brovkina A.F. Orbital diseases. Moscow: Medicina; 2008 (in Russian).

2. Shields J.A., Shields C.L. Rhabdomyosarcoma: review for the ophthalmologist. Surv. Ophthalmol. 2003; 48: 39–57. doi:10.1016/s0039-6257(02)00415-0

3. Turner J.H., Richmon J.D. Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol. Head Neck Surg. 2011; 145: 967–73. doi:10.1177/0194599811417063

4. Conneely M.F., Mafee M.F. Orbital rhabdomyosarcoma and simulating lesions. Neuroimaging Clin. N. Am. 2005; 15: 121–36. doi:10.1016/j.nic.2005.02.006

5. Koopman J.H., van der Heiden-van der Loo M., van Dijk M.R., Bijlsma W.R. Incidence of primary malignant orbital tumours in The Netherlands. Eye (Lond) 2011; 25: 461–5. doi:10.1038/eye.2011.9

6. Karcioglu Z.A., Hadjistilianou D., Rozans M., De Francesco S. Orbital rhabdomyosarcoma. Cancer Control. 2004; 11: 328–3. doi:10.1177/107327480401100507

7. Jung A., Bechthold S., Pfluger T., Renner C., Ehrt O. Orbital rhabdomyosarcoma in Noonan syndrome. J. Pediatr. Hematol. Oncol. 2003; 25: 330–2. doi:10.1097/00043426-200304000-00014

8. Thavaraj V., Sethi A., Arya L.S. Incomplete Beckwith–Wiedemann syndrome in a child with orbital rhabdomyosarcoma. Indian Pediatr. 2002 Mar; 39: 299–304. PMID: 11910143

9. Forstner D., Borg M., Saxon B. Orbital rhabdomyosarcoma: multidisciplinary treatment experience. Australas. Radiol. 2006; 50: 41–5. doi:10.1111/j.1440-1673.2005.01526.x

10. Sobel R.K., Ford J.R., Dong W., et al. Frequency and clinical course of residual orbital masses after treatment of orbital rhabdomyosarcoma. Am. J. Ophthalmol. 2021; 234: 28–36. doi:10.1016/j.ajo.2021.06.035

11. Arndt C., Tefft M., Gehan E., et al. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma study (IRS) IV pilot study. J. Pediatr. Hematol. Oncol. 1997; 19: 124–9. doi:10.1097/00043426-199703000-00005

12. Rao A.A., Chen J.Y., Robbins S.L., Ramkumar H.L. A clinical update and radiologic review of pediatric orbital and ocular tumors. J. Oncol. 2013; 2013: 975908. doi:10.1155/2013/975908

13. Chung E.M., Smirniotopoulos J.G., Specht C.S., Schroeder J.W., Cube R. From the archives of the AFIP: pediatric orbit tumors and tumorlike lesions: no osseous lesions of the extraocular orbit. Radiographics. 2007; 27: 1777–99. doi:10.1148/rg.276075138

14. Breneman J.C., Lyden E., Pappo A.S., et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the intergroup rhabdomyosarcoma study IV. J. Clin. Oncol. 2003; 21: 78–84. doi:10.1200/JCO.2003.06.129

15. Chisholm J.C., Marandet J., Rey A., et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J. Clin. Oncol. 2011; 29: 1319–25. doi:10.1200/JCO.2010.32.1984

16. Mazzoleni S., Bisogno G., Garaventa A., et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. 2005; 104: 183–90. doi:10.1002/cncr.21138

17. Yip C.C., Kersten R.C., McCulley T.J., Ballard E.T., Kulwin D.R. Osteogenic sarcoma after orbital radiation rhabdomyosarcoma. Ophthalmology. 2003; 110: 1996–99. doi:10.1016/S0161-6420(03)00478-0

18. Andreeva L.D., Khoroshilova-Maslova I.P. Immunomorphology in orbital rhabdomyosarcoma diagnostics. Vestnik oftal'mologii. 2009; 125 (2): 10–3 (in Russian).

19. Zhiltsova M.G., Valskiy V.V., Tsygankov A.Yu., Saakyan S.V. Cytological and immunocytochemical diagnostics of orbital rhabdomyosarcoma. Vestnik FGBU “RONC im. N.N. Blokhina”. 2016; 27 (4): 154–9 (in Russian).

20. Neudorfer M., Leibovitch I., Stolovitch C., et al. Intraorbital and periorbital tumors in children - value of ultrasound and color Doppler imaging in the differential diagnosis. Am. J. Ophthalmol. 2004; 137: 1065–72. doi:10.1016/j.ajo.2004.01.050

21. Sohaib S.A., Moseley I., Wright J.E. Orbital rhabdomyosarcoma — the radiological characteristics. Clin. Radiol. 1998; 53: 357–62. doi:10.1016/s0009-9260(98)80009-3

22. Andrade C.R., Takahama A., Nishimoto I.N., Kowalski L.P., Lopes M.A. Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases. Braz. Dent J. 2010; 21: 68–73. doi:10.1590/s0103-64402010000100011

23. Cintorino M., Vindigni C., Del Vecchio M.T., et al. Expression of actin isoforms and intermediate filament proteins in childhood orbital rhabdomyosarcomas. J. Submicrosc. Cytol. Pathol. 1989; 21: 409–19.

24. Missiaglia E., Williamson D., Chisholm J., et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 2012; 30: 1670–7. doi:10.1200/JCO.2011.38.5591